Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By BMS Drug
This article was originally published in PharmAsia News
U.S. FDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)
You may also be interested in...
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10
Eisai has pushed back the filing of its novel AMPA receptor antagonist perampanel for Parkinson's disease from fiscal 2007 to fiscal fourth quarter 2008 (ended March 31, 2009) in the U.S. and Europe because the drug failed to show an efficacy benefit over placebo in a Phase III study, Eisai said Oct. 30
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).